Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT03278665 |
Title | 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy (SENSITIZE) |
Acronym | SENSITIZE |
Recruitment | Completed |
Gender | both |
Phase | Phase Ib/II |
Variant Requirements | No |
Sponsors | 4SC AG |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | ITA | DEU |